Other names: Nucala
Description:
Mepolizumab (Nucala) is a biologic medication injected used to treat severe eosinophilic asthma. It is a monoclonal antibody that targets interleukin-5 (IL-5), a key cytokine responsible for the growth and survival of eosinophils, which play a significant role in airway inflammation in eosinophilic asthma. Approved for patients ≥6 years old with severe eosinophilic asthma that is not well-controlled with standard inhalers (e.g., corticosteroids, long-acting beta-agonists).
Treatment For:
AI generated Summary: Based on the single expert review, Mepolizumab appears to be an effective add-on treatment for severe eosinophilic asthma when other standard therapies fail to control symptoms adequately. It works by targeting IL-5 to reduce eosinophil-driven inflammation, resulting in fewer exacerbations, improved lung function, and potentially decreased reliance on oral steroids.
Mepolizumab is an add-on treatment for severe eosinophilic asthma, used when high-dose inhaled corticosteroids and other controllers fail to control symptoms. It reduces exacerbations, improves lung function, and may decrease oral steroid dependence by targeting IL-5 to lower eosinophil-driven inflammation.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
